08:00 , Feb 11, 2016 |  BC Innovations  |  Targets & Mechanisms

Complementary ideas

A Harvard team has mapped one of the strongest, and most difficult to decipher, genetic risk factors for schizophrenia to C4a, a molecule involved in the complement cascade. While the results offer a new therapeutic...
08:00 , Mar 6, 2006 |  BC Week In Review  |  Clinical News

TP10: Preliminary Phase IIb data

Preliminary data from a double-blind, placebo-controlled Phase IIb trial in 297 female patients showed that TP10 missed the primary endpoint. AVAN said that the trial confirmed a lack of efficacy in women that was observed...
07:00 , Oct 17, 2005 |  BC Week In Review  |  Clinical News

TP10: Completed Phase IIb enrollment

AVAN completed enrollment of 300 female subjects in a double-blind, placebo-controlled Phase IIb trial. Avant Immunotherapeutics Inc. (AVAN), Needham, Mass.   Product: TP10   Business: Cardiovascular   Molecular target: Complement 3 (C3) ; Complement 4b...
07:00 , Oct 25, 2004 |  BC Week In Review  |  Clinical News

TP10: Phase IIb ongoing

AVAN announced that its double-blind, placebo-controlled, U.S. Phase IIb trial in 300 female patients, originally to be completed by year end, will now be completed in the 1H05. Avant Immunotherapeutics Inc. (AVAN), Needham, Mass.  ...
07:00 , Oct 11, 2004 |  BioCentury  |  Product Development

Cardiovascular pipeline

Cardiovascular pipeline Company Product Target Description Indication Status Alexion/ Procter & Gamble Pexelizumab (5G1.1-SC) Complement 5 (C5) Humanized single chain MAb targeting C5 Coronary artery bypass graft (CABG) surgery; myocardial infarction (MI) Ph III Amylin...
07:00 , Oct 11, 2004 |  BioCentury  |  Product Development

The heart of inflammation

Inflammation is a complex network of interactions that arises in response to tissue injury, regardless of the site or nature of the initiating event. Despite this virtual omnipresence of the inflammatory process throughout the body,...
08:00 , Feb 23, 2004 |  BC Week In Review  |  Clinical News

TP10: Phase IIb

AVAN will start this quarter a double-blind, placebo-controlled, U.S. Phase IIb trial in 300 female patients. In a Phase II trial, TP10 significantly decreased the primary endpoint of the composite incidence of mortality, MI, prolonged...
08:00 , Feb 17, 2004 |  BC Extra  |  Clinical News

Avant starts TP10 Phase IIb

AVAN started a double-blind, placebo-controlled Phase II trial of its TP10 to reduce the incidence of death and heart attack in 300 female patients undergoing cardiopulmonary bypass (CPB) surgery. AVAN expects the U.S. trial to...
08:00 , Nov 17, 2003 |  BC Week In Review  |  Clinical News

TP10: Phase II

Previously reported data from a Phase II trial in 564 patients showed TP10 significantly decreased the composite primary endpoint in male patients compared to placebo (p=0.01). No significant decreases in the composite endpoint were seen...
07:00 , May 5, 2003 |  BC Week In Review  |  Clinical News

TP10: Phase II

Additional analysis of a U.S. placebo-controlled Phase II trial in 564 patients undergoing high risk cardiac surgery showed male patients had a 36% reduction in the primary endpoint of mortality, MI, prolonged intubation and prolonged...